I've been a little unclear about how many courses delivered when, etc. The info is out there in pieces. I listened to the beginning of the recent conference call, the one that was made May 6 before the written report.
Eric Rose said that in March 190,000 courses had been delivered at a price of about $25 million. That puts the price at $131.58 per course. The recent written announcement says that "nearly 200,000 courses of Arestvyr" were delivered recently. Again in the spoken remarks, I think he said that there would be 3 deliveries of about 190,000. Folding all that together, the first invoice should be about $75 million. If the third delivery is completed within 3 months from the May 6 call, that means that the invoice can go out in early August, in agreement with mymygbye .
Assuming these deliveries are seamless, next billing would Feb/march '14 and again in Sept/Oct '14 and that would satisfy this contract. When would stuff on shelf now need to be replaced due to shelf life?
Can anybody add detail? In this series of deliveries, how many courses and how much money? How much additional cash relates to FDA approval and other milestones? And of course the shelf-life issue and other opportunities for further sales?